Abstract
BACKGROUND Findings from clinical trials of proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors have led to concern that these drugs or t......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
